Want to learn more about the latest in using plasma exchange in ANCA-associated vasculitis? (if you’re a nephrologist, of course you do!)
Check out this rapid summary below!
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
Want to learn more about the latest in using plasma exchange in ANCA-associated vasculitis? (if you’re a nephrologist, of course you do!)
Check out this rapid summary below!
✳️ #TenTweetNephJC ✳️
— Nephrology Jrnl Club (@NephJC) April 8, 2022
👉 where we catch you up on the week's #NephJC chat in 10 tweets
The topic at hand was Plasma Exchange and Vasculitis: the infamous debate of to PLEX or not to PLEX in AAV
Check out this thread to see if you change your mind on this comPLEX topic 👇 pic.twitter.com/PvW0C0O9R9